SEC Form 4 · accession 0001140361-15-012694
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Austin Gurney
Officer — See Remarks
Period of report
Mar 17, 2015
Accepted (ET)
Mar 19, 2015 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F4 | Mar 17, 2015 | S | 4,000 | $27.3674 | D | 71,419 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 16, 2014.
- F2This transaction was executed in multiple trades in prices ranging from $27.06 to $27.82, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
- F4Includes 1,285 shares acquired under the Issuer's Employee Stock Purchase Plan on February 27, 2015.
Remarks
Senior Vice President, Molecular and Cellular Biology